Cross-trial analysis of immunologic and clinical data resulting from phase i and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients

Journal of Immunotherapy

Volumn 33, Issue 9, 2010, Pages 999-1005

  Harrop, Richard ^a   Shingler, William ^a   Kelleher, Michelle ^a   De Belin, Jackie ^a   Treasure, Peter ^b  

^a OXFORD BIOMEDICA UK LTD   (United Kingdom)

^b Peter Treasure Statistical Services Ltd   (United Kingdom)

Author keywords

antibody; antigen; colorectal; immunotherapy; vaccine

Indexed keywords

ALPHA INTERFERON; ANTIBODY; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; IRINOTECAN; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; OXALIPLATIN; VIRUS VECTOR;

ADVANCED CANCER; AGE; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN SPECIFICITY; ARTICLE; BLOOD SAMPLING; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DRUG MEGADOSE; EXPLORATORY RESEARCH; GENDER; HUMAN; IMMUNE RESPONSE; KIDNEY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; VACCINATION;

ADULT; ANTIGENS, NEOPLASM; CANCER VACCINES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNITY, HUMORAL; KIDNEY NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; VACCINATION;

EID: 78149282337     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181f5dac7     Document Type: Article

References (21)

1. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28:1099-1105.
2. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115:3670-3679.
3. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleu-cel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24:3089-3094.
4. Rini BI, Weinberg V, Fong L, et al. Combination immuno-therapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer. 2006;107:67-74.
5. Starzynska T, Marsh PJ, Schofield PF, et al. Prognostic significance of 5T4 oncofet al. antigen expression in colorectal carcinoma. Br J Cancer. 1994;69:899-902.
6. Southall PJ, Boxer GM, Bagshawe KD, et al. Immunohisto-logical distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer. 1990;61:89-95.
7. Hole N, Stern PL. A 72kD trophoblast glycoprotein defined by a monoclonal antibody. Br J Cancer. 1988;57:239-246.
8. Griffiths RW, Gilham DE, Dangoor A, et al. Expression of the 5T4 oncofoet al. antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy. Br J Cancer. 2005;93:670-677.
9. Starzynska T, Rahi V, Stern PL. The expression of 5T4 antigen in colorectal and gastric carcinoma. Br J Cancer. 1992;66:867-869.
10. Jones H, Roberts G, Hole N, et al. Investigation of expression of 5T4 antigen in cervical cancer. Br J Cancer. 1990;61:96-100.
11. Wrigley E, McGown AT, Rennison J, et al. 5T4 oncofet al. antigen expression in ovarian carcinoma. Int J Gynecol Cancer. 1995;5:269-274.
12. Harrop R, Connolly N, Redchenko I, et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res. 2006;12:3416-3424.
13. Elkord E, Dangoor A, Drury NL, et al. An MVA-based vaccine targeting the oncofet al. antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases. J Immunother. 2008;31:820-829.
14. Kaufman HL, Taback B, Sherman W, et al. Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J Transl Med. 2009;7:2.
15. Hawkins RE, Macdermott C, Shablak A, et al. Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha. J Immunother. 2009;32:424-429.
16. Amato RJ, Shingler W, Goonewardena M, et al. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial. J Immunother. 2009;32:765-772.
17. Amato RJ, Shingler W, Naylor S, et al. Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial. Clin Cancer Res. 2008;14:7504-7510.
18. Amato RJ, Drury N, Naylor S, et al. Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial. J Immunother. 2008;31:577-585.
19. Harrop R, Drury N, Shingler W, et al. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin, and irinotecan) is safe and induces potent immune responses. Cancer Immunol Immunother. 2008;57:977-986.
20. Harrop R, Drury N, Shingler W, et al. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res. 2007;13:4487-4494.
21. Reuschenbach M, von Knebel Doeberitz M, Wentzensen N. A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother. 2009;58:1535-1544.